Clinical Challenges: JAK Inhibitors for Atopic Dermatitis

Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings

Related Keywords

Washington ,United States ,Chicago ,Illinois ,Connecticut ,New Haven ,New York ,Americans ,Brett King ,Amys Paller ,Lawrencef Eichenfield ,Jonathan Silverberg ,Cameron Rokhsar ,Chris Bunick ,Kristin Jenkins ,Yale School Of Medicine ,University Of California San Diego ,Northwestern University Feinberg School Of Medicine ,Health Sciences ,George Washington University School Of Medicine ,California San Diego ,Northwestern University Feinberg School ,Mount Sinai Hospital ,George Washington University School ,Yale School ,Eczema Area ,Severity Index ,Medpage Today ,Reading Room ,Atopic Dermatitis ,Upadacitinib ,Dupilumab ,Malignancy ,Dermatology ,